The outcome of Pleurodesis in Malignant Pleural Effusion
No subtitle
DOI:
https://doi.org/10.32007/jfacmedbagdad.6411884Keywords:
Key words: pleurodesis, malignant effusion, Bleomycin .TalcAbstract
Background: Accumulation of fluid in pleural space, which is malignant in nature, is secondary to lung, breast or ovarian tumors. Metastatic Adeno Ca is most commonly seen in male and breast Ca is most commonly seen in female. It indicates advanced disease and reduced survival.
Aim: Is to study prospectively thirty patients with malignant pleural effusion according to their clinical presentation, ways of diagnosis, and methods of chemical pleurodesis.
Patient and methods: Data of thirty patients with malignant pleural effusion collected and analyzed using a form to categorize them according to their age, gender, presenting features, imaging studies and procedure performed to drain the fluid and to arrange chemical pleurodesis.
Results: Eighteen patients were male; twelve patients were female in a ratio of 1.5:1. The youngest was 52 years old while the oldest was 81 years old. The mean age was 65.8 ±7.34. The most frequent presenting features were cough and dyspnea. Imaging studies showed that eleven patients had left sided effusion with underlying mass. Eight patients had right sided effusion with underlying mass while the remaining eleven patients had only effusion. Twenty patients received (Talc) and ten patients received (Bleomycin) with comparable recurrence rate of the effusion, in seven patients out of 20 in Talc (35%) and in three out of 10 patients received Bleomycin (30%).
Conclusion: Malignant pleural effusion should be drained nearly complete evacuation; regardless the primary cause, prior to installation of agent for pleurodesis and both (Talc & Bleomycin) can be used with comparable results and recurrence
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 waleed M. hussen, Ali H. Said, Osama Elhassani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.